Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.78 NOK | +8.53% | +6.33% | -26.26% |
May. 14 | Transcript : Nykode Therapeutics AS, Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 140M 13.32M | Sales 2025 * | 191M 18.23M | Capitalization | 5.15B 491M |
---|---|---|---|---|---|
Net income 2024 * | -612M -58.37M | Net income 2025 * | -740M -70.57M | EV / Sales 2024 * | 28 x |
Net cash position 2024 * | 1.25B 119M | Net cash position 2025 * | 1.01B 95.89M | EV / Sales 2025 * | 21.7 x |
P/E ratio 2024 * |
-8.44
x | P/E ratio 2025 * |
-7.56
x | Employees | 172 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55% |
Latest transcript on Nykode Therapeutics
1 day | +8.53% | ||
1 week | +6.33% | ||
1 month | +18.03% | ||
3 months | -5.00% | ||
6 months | -11.05% | ||
Current year | -26.26% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 47 | 06-12-31 | |
Michael Engsig
CEO | Chief Executive Officer | - | 07-02-28 |
Harald Gurvin
DFI | Director of Finance/CFO | 49 | 21-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | - |
Director/Board Member | 64 | - | |
Director/Board Member | - | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 746 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 146 M€ | -2.63% | - | |
0.00% | 25 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 15.78 | +8.53% | 3,752,664 |
24-05-30 | 14.54 | -0.14% | 498,970 |
24-05-29 | 14.56 | -3.00% | 739,643 |
24-05-28 | 15.01 | +1.90% | 1,450,451 |
24-05-27 | 14.73 | -0.74% | 698,518 |
Real-time Oslo Bors, May 31, 2024 at 10:45 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.26% | 451M | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- VACC Stock